442 related articles for article (PubMed ID: 32947121)
1. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data.
Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Oliveros-Acebes E; García-Navarro MJ; Khosravi-Shahi P
Cancer Treat Rev; 2020 Nov; 90():102102. PubMed ID: 32947121
[TBL] [Abstract][Full Text] [Related]
2. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
Yazaki S; Yoshida T; Kojima Y; Yagishita S; Nakahama H; Okinaka K; Matsushita H; Shiotsuka M; Kobayashi O; Iwata S; Narita Y; Ohba A; Takahashi M; Iwasa S; Kobayashi K; Ohe Y; Yoshida T; Hamada A; Doi T; Yamamoto N
JAMA Oncol; 2021 Aug; 7(8):1141-1148. PubMed ID: 34047762
[TBL] [Abstract][Full Text] [Related]
3. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
[TBL] [Abstract][Full Text] [Related]
5. Review of risk of COVID-19 in cancer patients and their cohabitants.
Palka-Kotlowska M; Custodio-Cabello S; Oliveros-Acebes E; Khosravi-Shahi P; Cabezón-Gutierrez L
Int J Infect Dis; 2021 Apr; 105():15-20. PubMed ID: 33556611
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.
van Dam P; Huizing M; Roelant E; Hotterbeekx A; De Winter FHR; Kumar-Singh S; Moons P; Amajoud Z; Vulsteke C; Croes L; Janssens A; Berneman Z; Prenen H; Meuris L; Vanden Berghe W; Smits E; Peeters M
Eur J Cancer; 2021 May; 148():328-339. PubMed ID: 33773276
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
8. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.
Shu H; Wang S; Ruan S; Wang Y; Zhang J; Yuan Y; Liu H; Wu Y; Li R; Pan S; Ouyang Y; Yuan S; Zhou P; Shang Y
Virol Sin; 2020 Dec; 35(6):744-751. PubMed ID: 32720214
[TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of Immunoglobulin M and G Antibodies against SARS-CoV-2 Virus: A Systematic Review and Meta-Analysis Study.
Fathi M; Vakili K; Sayehmiri F; Mohamadkhani A; Ghanbari R; Hajiesmaeili M; Rezaei-Tavirani M
Iran J Immunol; 2021 Mar; 18(1):34-46. PubMed ID: 33787512
[TBL] [Abstract][Full Text] [Related]
10. Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG-IgM antibody rapid tests points to IgM as the Achilles heel.
Mboumba Bouassa RS; Péré H; Tonen-Wolyec S; Longo JD; Moussa S; Mbopi-Keou FX; Mossoro-Kpinde CD; Grésenguet G; Veyer D; Bélec L
J Med Virol; 2021 Apr; 93(4):2196-2203. PubMed ID: 33107601
[TBL] [Abstract][Full Text] [Related]
11. Highlighted Prospects of an IgM/IgG Antibodies Test in Identifying Individuals With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
Li Y; He Q; Yu R; Jiang H; Wang W; Feng D; Hou G; Zhou H; Jiang Y; Xiang Z
Arch Pathol Lab Med; 2021 Jan; 145(1):39-45. PubMed ID: 32966561
[TBL] [Abstract][Full Text] [Related]
12. Relationship between viral load, infection-to-delivery interval and mother-to-child transfer of anti-SARS-CoV-2 antibodies.
Poon LC; Leung BW; Ma T; Yu FNY; Kong CW; Lo TK; So PL; Leung WC; Shu W; Cheung KW; Moungmaithong S; Wang CC
Ultrasound Obstet Gynecol; 2021 Jun; 57(6):974-978. PubMed ID: 33798280
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic.
Javadinia SA; Ariamanesh M; Nabavifard M; Porouhan P; PeyroShabany B; Fazilat-Panah D; Hatami F; Ghasemi A; Lyman GH; Welsh JS; Ashkar Tizabi S; Dehghani M
Cancer Invest; 2022 Feb; 40(2):115-123. PubMed ID: 34699294
[TBL] [Abstract][Full Text] [Related]
14. The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19.
Qin X; Shen J; Dai E; Li H; Tang G; Zhang L; Hou X; Lu M; Wu X; Duan S; Zhang J; Tsoi MF; Jiang P; Li Y
BMC Immunol; 2021 Feb; 22(1):14. PubMed ID: 33596826
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.
Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG
BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620
[TBL] [Abstract][Full Text] [Related]
16. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
Front Public Health; 2022; 10():967447. PubMed ID: 36276377
[TBL] [Abstract][Full Text] [Related]
17. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis.
Li Z; Yi Y; Luo X; Xiong N; Liu Y; Li S; Sun R; Wang Y; Hu B; Chen W; Zhang Y; Wang J; Huang B; Lin Y; Yang J; Cai W; Wang X; Cheng J; Chen Z; Sun K; Pan W; Zhan Z; Chen L; Ye F
J Med Virol; 2020 Sep; 92(9):1518-1524. PubMed ID: 32104917
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study.
Spinelli MA; Lynch KL; Yun C; Glidden DV; Peluso MJ; Henrich TJ; Gandhi M; Brown LB
Lancet HIV; 2021 Jun; 8(6):e334-e341. PubMed ID: 33933189
[TBL] [Abstract][Full Text] [Related]
19. False-positive results of SARS-CoV-2 IgM/IgG antibody tests in sera stored before the 2020 pandemic in Italy.
Latiano A; Tavano F; Panza A; Palmieri O; Niro GA; Andriulli N; Latiano T; Corritore G; Gioffreda D; Gentile A; Fontana R; Guerra M; Biscaglia G; Bossa F; Carella M; Miscio G; di Mauro L
Int J Infect Dis; 2021 Mar; 104():159-163. PubMed ID: 33383223
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of seroprevalence in a cohort of university students of Rome (Italy) between September 2020 and July 2021.
Ulivieri A; Morgante A; Magi F; Salehi LB; Lavra L
Epidemiol Prev; 2022; 46(5-6):367-375. PubMed ID: 36628641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
